Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma

The main objective of this prospective study is to evaluate the effectiveness and safety of a novel neoadjuvant therapy for patients with locally advanced sinonasal carcinoma (SNC). The treatment consists of the standard TP chemotherapy regimen (docetaxel and cisplatin) combined with dual immunotherapy (sintilimab and ipilimumab N01) administered before surgery. Researchers aim to determine the major pathological response (MPR) rate and long-term survival outcomes, while also exploring if this combination treatment approach can help better preserve critical facial and organ functions for SNC patients.

NCT Number	NCT07645846
Lead Sponsor	Sun Yat-sen University Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Nanfang Hospital, Southern Medical University, First Affiliated Hospital, Sun Yat-Sen University, Zhujiang Hospital, Qingyuan People's Hospital, Guangdong Provincial People's Hospital
Conditions	Locally Advanced Sinonasal Carcinoma
Enrollment	23 participants
Start Date	2026-07-31
Primary Completion	2028-08-01 (estimated)
Study Completion	2030-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-25